secwatch / observer
8-K filed August 3, 2021, 7:59 PM ET ticker BCRX CIK 0000882796
leadership confidence high sentiment neutral materiality 0.40

BioCryst Chief Business Officer Megan Sniecinski Departs

BIOCRYST PHARMACEUTICALS INC

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Megan Sniecinski

Chief Business Officer
BCRX · BIOCRYST PHARMACEUTICALS INC
Effective
2021-07-28
Filed
August 3, 2021, 7:59 PM ET
On July 28, 2021, it was determined that Megan Sniecinski, Chief Business Officer of BioCryst Pharmaceuticals, Inc. (the “Company”), would separate from employment with the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Megan Sniecinski departed as Chief Business Officer at BIOCRYST PHARMACEUTICALS INC.

Action
separated
Role
Chief Business Officer
Exact text from the filing
On July 28, 2021, it was determined that Megan Sniecinski, Chief Business Officer of BioCryst Pharmaceuticals, Inc. (the “Company”), would separate from employment with the Company.
View on SEC.gov

BIOCRYST PHARMACEUTICALS INC filing history →

Source: SEC EDGAR
accession 0001171843-21-005448
view filing index on sec.gov
view primary document
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.